Terrie Terrell
Registered Nurse · Oklahoma City, OKNPI 1891205209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,852 of the $5,932 with a category attached, or 81.8%. 18 manufacturers reported payments, led by Boston Scientific at 31.3% of the total. Reporting peaked in 2024 at $2,843 and has fallen 67.3% since, to $930 in 2025. Among registered nurse clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $57.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novo Nordisk$915
- Merck$779
- E.r. Squibb & Sons, L.L.C.$619
- Johnson & Johnson$247
- Actelion Pharmaceuticals US, Inc.$237
- plus $1K from 12 others
What the payments were for
- Travel & lodging$98217%
- Food & beverage$4,85282%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $1,859 |
| Novo Nordisk | 15 | $915 |
| Merck | 23 | $779 |
| E.r. Squibb & Sons, L.L.C. | 12 | $619 |
| Johnson & Johnson | 3 | $247 |
| Actelion Pharmaceuticals US, Inc. | 4 | $237 |
| AstraZeneca | 2 | $235 |
| Esperion Therapeutics, Inc. | 2 | $232 |
| Boehringer Ingelheim | 9 | $168 |
| Pfizer | 5 | $164 |
| Amgen | 2 | $130 |
| Novartis | 7 | $122 |
| Edwards Lifesciences | 1 | $69 |
| Bayer | 4 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $39 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,932 in reported general payments places this provider in the 95th percentile of 23 registered nurse providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $77,228 |
| EntrestoSacubitril/Valsartan | 39 | $41,692 |
| JardianceEmpagliflozin | 33 | $32,247 |
| OzempicSemaglutide | 12 | $18,925 |
| FarxigaDapagliflozin Propanediol | 12 | $8,988 |
| Olmesartan Medoxomil | 61 | $1,897 |
| Verapamil ErVerapamil Hcl | 51 | $1,596 |
| Clonidine | 11 | $1,553 |
| Metoprolol Succinate | 65 | $1,526 |
| Losartan Potassium | 92 | $1,305 |
| Atorvastatin Calcium | 76 | $1,154 |
| Nebivolol Hcl | 17 | $1,107 |
| Carvedilol | 88 | $1,106 |
| Rosuvastatin Calcium | 51 | $974 |
| Ezetimibe | 23 | $957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $77,22858 claims |
| NovartisEntresto | $122 | $41,69239 claims |
| Boehringer IngelheimJardiance | $168 | $32,24733 claims |
| Novo NordiskOzempic | $915 | $18,92512 claims |
| AstraZenecaFarxiga | $235 | $8,98812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 registered nurse providers in Oklahoma.
Other registered nurse in Oklahoma City
- Hillary WhiteOklahoma City$3K
- Robin JohnsonOklahoma City$1K
- Arjun PillaiOklahoma City$81
- Joshy ShabuOklahoma City$30
- Samuel NjorogeOklahoma City$29
- Melissa CaseOklahoma City$18
- Wanda Meler-PoteetOklahoma City$18
- Patricia StevensonSkiatook$726K
- Leslie JeffriesMcAlester$941
- Larmeta GettesNorman$362
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.